ComprExIT
Collection
ComprExIT context-compression models and ICAE baselines: 1B/3B/8B, 4x compression, NTP and SFT variants. • 18 items • Updated • 1
Dataset Preview
The full dataset viewer is not available (click to read why). Only showing a preview of the rows.
The dataset generation failed
Error code: DatasetGenerationError
Exception: TypeError
Message: Couldn't cast array of type
struct<question: string, answers: list<item: string>, qid: string, question_tokens: list<item: list<item: string>>, is_impossible: bool, detected_answers: list<item: struct<text: string, token_spans: list<item: list<item: int64>>, char_spans: list<item: list<item: int64>>>>>
to
{'question': Value('string'), 'answers': List(Value('string')), 'qid': Value('string'), 'question_tokens': List(List(Json(decode=True))), 'detected_answers': List({'text': Value('string'), 'token_spans': List(List(Value('int64'))), 'char_spans': List(List(Value('int64')))})}
Traceback: Traceback (most recent call last):
File "/usr/local/lib/python3.14/site-packages/datasets/builder.py", line 1816, in _prepare_split_single
for key, table in generator:
^^^^^^^^^
File "/src/services/worker/src/worker/job_runners/config/parquet_and_info.py", line 613, in wrapped
for item in generator(*args, **kwargs):
~~~~~~~~~^^^^^^^^^^^^^^^^^
File "/usr/local/lib/python3.14/site-packages/datasets/packaged_modules/json/json.py", line 343, in _generate_tables
self._cast_table(pa_table, json_field_paths=json_field_paths),
~~~~~~~~~~~~~~~~^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
File "/usr/local/lib/python3.14/site-packages/datasets/packaged_modules/json/json.py", line 132, in _cast_table
pa_table = table_cast(pa_table, self.info.features.arrow_schema)
File "/usr/local/lib/python3.14/site-packages/datasets/table.py", line 2369, in table_cast
return cast_table_to_schema(table, schema)
File "/usr/local/lib/python3.14/site-packages/datasets/table.py", line 2303, in cast_table_to_schema
cast_array_to_feature(
~~~~~~~~~~~~~~~~~~~~~^
table[name] if name in table_column_names else pa.array([None] * len(table), type=schema.field(name).type),
^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
feature,
^^^^^^^^
)
^
File "/usr/local/lib/python3.14/site-packages/datasets/table.py", line 1852, in wrapper
return pa.chunked_array([func(chunk, *args, **kwargs) for chunk in array.chunks])
~~~~^^^^^^^^^^^^^^^^^^^^^^^^
File "/usr/local/lib/python3.14/site-packages/datasets/table.py", line 2109, in cast_array_to_feature
casted_array_values = _c(array.values, feature.feature)
File "/usr/local/lib/python3.14/site-packages/datasets/table.py", line 1854, in wrapper
return func(array, *args, **kwargs)
File "/usr/local/lib/python3.14/site-packages/datasets/table.py", line 2149, in cast_array_to_feature
raise TypeError(f"Couldn't cast array of type\n{_short_str(array.type)}\nto\n{_short_str(feature)}")
TypeError: Couldn't cast array of type
struct<question: string, answers: list<item: string>, qid: string, question_tokens: list<item: list<item: string>>, is_impossible: bool, detected_answers: list<item: struct<text: string, token_spans: list<item: list<item: int64>>, char_spans: list<item: list<item: int64>>>>>
to
{'question': Value('string'), 'answers': List(Value('string')), 'qid': Value('string'), 'question_tokens': List(List(Json(decode=True))), 'detected_answers': List({'text': Value('string'), 'token_spans': List(List(Value('int64'))), 'char_spans': List(List(Value('int64')))})}
The above exception was the direct cause of the following exception:
Traceback (most recent call last):
File "/src/services/worker/src/worker/job_runners/config/parquet_and_info.py", line 1369, in compute_config_parquet_and_info_response
parquet_operations, partial, estimated_dataset_info = stream_convert_to_parquet(
~~~~~~~~~~~~~~~~~~~~~~~~~^
builder, max_dataset_size_bytes=max_dataset_size_bytes
^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
)
^
File "/src/services/worker/src/worker/job_runners/config/parquet_and_info.py", line 948, in stream_convert_to_parquet
builder._prepare_split(split_generator=splits_generators[split], file_format="parquet")
~~~~~~~~~~~~~~~~~~~~~~^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
File "/usr/local/lib/python3.14/site-packages/datasets/builder.py", line 1683, in _prepare_split
for job_id, done, content in self._prepare_split_single(
~~~~~~~~~~~~~~~~~~~~~~~~~~^
gen_kwargs=gen_kwargs, job_id=job_id, **_prepare_split_args
^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
):
^
File "/usr/local/lib/python3.14/site-packages/datasets/builder.py", line 1869, in _prepare_split_single
raise DatasetGenerationError("An error occurred while generating the dataset") from e
datasets.exceptions.DatasetGenerationError: An error occurred while generating the datasetNeed help to make the dataset viewer work? Make sure to review how to configure the dataset viewer, and open a discussion for direct support.
context string | qas list | context_tokens list | header dict |
|---|---|---|---|
null | null | null | {
"dataset": "BioASQ",
"split": "dev"
} |
Neutrophil elastase gene (ELANE) mutations are responsible for the majority of cases of severe congenital neutropenia (CN) and cyclic neutropenia (CyN). We screened CN (n = 395) or CyN (n = 92) patients for ELANE mutations and investigated the impact of mutations on mRNA expression, protein expression, and activity. We... | [
{
"question": "Which gene is most commonly associated with severe congenital and cyclic neutropenia?",
"answers": [
"The neutrophil elastase gene (ELANE)"
],
"qid": "2cf03749226444fea30c672c678b3d63",
"question_tokens": [
[
"Which",
0
],
[
"gene",
... | [
[
"Neutrophil",
0
],
[
"elastase",
11
],
[
"gene",
20
],
[
"(",
25
],
[
"ELANE",
26
],
[
")",
31
],
[
"mutations",
33
],
[
"are",
43
],
[
"responsible",
47
],
[
"for",
59
],
[
"the",
63
... | null |
Tardive dyskinesia (TD) is a movement disorder characterized by abnormal involuntary facial movements induced by chronic therapy with classical antipsychotic medications. Currently, there is no satisfactory pharmacotherapy for TD, which represents a major limitation to therapy with classical antipsychotics. In order to... | [
{
"question": "What is the cause of Tardive dyskinesia?",
"answers": [
"Tardive dyskinesia (TD) is a movement disorder characterized by abnormal involuntary facial movements induced by chronic therapy with classical antipsychotic medications."
],
"qid": "b0f3562cb2574620ba46ae33c88d65b3",
... | [
[
"Tardive",
0
],
[
"dyskinesia",
8
],
[
"(",
19
],
[
"TD",
20
],
[
")",
22
],
[
"is",
24
],
[
"a",
27
],
[
"movement",
29
],
[
"disorder",
38
],
[
"characterized",
47
],
[
"by",
61
],
... | null |
We investigated high- or low-dose irradiation-responsive proteins using proteomics on two-dimensional (2D) PAGE, and the effects of ageing on cell responses to radiation in variously aged rat astrocytes. After 5 Gy irradiation, the relative abundance of peroxiredoxin 2, an antioxidant enzyme, and latexin, an inhibitor ... | [
{
"question": "What type of enzyme is peroxiredoxin 2 (PRDX2)?",
"answers": [
"antioxidant"
],
"qid": "b7cd2f0a380d4d14b488e20ddf88b204",
"question_tokens": [
[
"What",
0
],
[
"type",
5
],
[
"of",
10
],
... | [
[
"We",
0
],
[
"investigated",
3
],
[
"high-",
16
],
[
"or",
22
],
[
"low",
25
],
[
0,
28
],
[
"dose",
29
],
[
"irradiation",
34
],
[
0,
45
],
[
"responsive",
46
],
[
"proteins",
57
],
... | null |
Suppression subtractive hybridization performed on Down syndrome (DS) versus control fetal brains revealed differential expression of peroxiredoxin 2 (PRDX2), mapped at 13q12. Peroxiredoxins are antioxidant enzymes involved in protein and lipid protection against oxidative injury and in cellular signalling pathways reg... | [
{
"question": "What type of enzyme is peroxiredoxin 2 (PRDX2)?",
"answers": [
"antioxidant"
],
"qid": "733e977ad4f14caf9148b8dbb151fd8c",
"question_tokens": [
[
"What",
0
],
[
"type",
5
],
[
"of",
10
],
... | [
[
"Suppression",
0
],
[
"subtractive",
12
],
[
"hybridization",
24
],
[
"performed",
38
],
[
"on",
48
],
[
"Down",
51
],
[
"syndrome",
56
],
[
"(",
65
],
[
"DS",
66
],
[
")",
68
],
[
"versus",... | null |
Peroxiredoxin 2 (PRDX2) has been known to act as an antioxidant enzyme whose main function is H(2)O(2) reduction in cells. We aimed to study the expression patterns of PRDX2 in mouse ovaries and explore the function of this protein in apoptosis of granulosa cells (GCs). We found that the expression of the PRDX2 protein... | [
{
"question": "What type of enzyme is peroxiredoxin 2 (PRDX2)?",
"answers": [
"antioxidant"
],
"qid": "c3addb03d57c47208e8a84201cdf7608",
"question_tokens": [
[
"What",
0
],
[
"type",
5
],
[
"of",
10
],
... | [
[
"Peroxiredoxin",
0
],
[
2,
14
],
[
"(",
16
],
[
"PRDX2",
17
],
[
")",
22
],
[
"has",
24
],
[
"been",
28
],
[
"known",
33
],
[
"to",
39
],
[
"act",
42
],
[
"as",
46
],
[
"an",
... | null |
Peroxiredoxin 2 (Prx2) is an antioxidant enzyme that uses cysteine residues to decompose peroxides. Prx2 is the third most abundant protein in erythrocytes, and competes effectively with catalase and glutathione peroxidase to scavenge low levels of hydrogen peroxide, including that derived from hemoglobin autoxidation.... | [
{
"question": "What type of enzyme is peroxiredoxin 2 (PRDX2)?",
"answers": [
"antioxidant"
],
"qid": "26a83e722adc4516a5e0f6a8f7c8caaa",
"question_tokens": [
[
"What",
0
],
[
"type",
5
],
[
"of",
10
],
... | [
[
"Peroxiredoxin",
0
],
[
2,
14
],
[
"(",
16
],
[
"Prx2",
17
],
[
")",
21
],
[
"is",
23
],
[
"an",
26
],
[
"antioxidant",
29
],
[
"enzyme",
41
],
[
"that",
48
],
[
"uses",
53
],
[
... | null |
Reactive oxygen species are involved in ovulation. The aim of this study was to examine gonadotropin regulation of antioxidant enzyme sulfiredoxin (Srx) and peroxiredoxin 2 (PRDX2) expressions and modification during the ovulatory process in rats. Administration of antioxidants in vivo reduced ovulation rate and cumulu... | [
{
"question": "What type of enzyme is peroxiredoxin 2 (PRDX2)?",
"answers": [
"antioxidant"
],
"qid": "b7b765a669484522bfdfa013ced2bc9d",
"question_tokens": [
[
"What",
0
],
[
"type",
5
],
[
"of",
10
],
... | [
[
"Reactive",
0
],
[
"oxygen",
9
],
[
"species",
16
],
[
"are",
24
],
[
"involved",
28
],
[
"in",
37
],
[
"ovulation",
40
],
[
".",
49
],
[
"The",
51
],
[
"aim",
55
],
[
"of",
59
],
[
... | null |
Recent evidence suggests that abnormal activation of cyclin-dependent kinase 5 (cdk5) is a critical prodeath signal in stroke. However, the mechanism(s) by which cdk5 promotes death is unclear. Complicating the role of cdk5 are the observations that cdk5 can exist in multiple cellular regions and possess both prosurviv... | [
{
"question": "What type of enzyme is peroxiredoxin 2 (PRDX2)?",
"answers": [
"antioxidant"
],
"qid": "1907600356cb4afeb53267a9f83291d7",
"question_tokens": [
[
"What",
0
],
[
"type",
5
],
[
"of",
10
],
... | [
[
"Recent",
0
],
[
"evidence",
7
],
[
"suggests",
16
],
[
"that",
25
],
[
"abnormal",
30
],
[
"activation",
39
],
[
"of",
50
],
[
"cyclin",
53
],
[
0,
59
],
[
"dependent",
60
],
[
"kinase",
... | null |
Many studies have reported that the generation of reactive oxygen species (ROS) increases during the differentiation of muscle-derived C2C12 cells. Peroxiredoxin-2 (Prx-2) is an abundant mammalian enzyme that protects against oxidative stress. However, the role of Prx-2 in muscle differentiation has not been investigat... | [
{
"question": "What type of enzyme is peroxiredoxin 2 (PRDX2)?",
"answers": [
"antioxidant"
],
"qid": "4f34ebb86bd542e3a0ce6e21de3fe86a",
"question_tokens": [
[
"What",
0
],
[
"type",
5
],
[
"of",
10
],
... | [
[
"Many",
0
],
[
"studies",
5
],
[
"have",
13
],
[
"reported",
18
],
[
"that",
27
],
[
"the",
32
],
[
"generation",
36
],
[
"of",
47
],
[
"reactive",
50
],
[
"oxygen",
59
],
[
"species",
6... | null |
The mechanisms underlying lithium's therapeutic efficacy in the chronic treatment of bipolar disorder are not clearly understood. Useful insights can be obtained by identifying genes that are differentially regulated during chronic lithium treatment. Toward this end, we have used microarray technology to identify mRNAs... | [
{
"question": "What type of enzyme is peroxiredoxin 2 (PRDX2)?",
"answers": [
"antioxidant"
],
"qid": "f1d83c49ddc1460baffb741b5751e1c2",
"question_tokens": [
[
"What",
0
],
[
"type",
5
],
[
"of",
10
],
... | [
[
"The",
0
],
[
"mechanisms",
4
],
[
"underlying",
15
],
[
"lithium",
26
],
[
"'s",
33
],
[
"therapeutic",
36
],
[
"efficacy",
48
],
[
"in",
57
],
[
"the",
60
],
[
"chronic",
64
],
[
"treatmen... | null |
In melanoma, transition to the vertical growth phase is the critical step in conversion to a deadly malignant disease. Here, we offer the first evidence that an antioxidant enzyme has a key role in this transition. We found that the antioxidant enzyme peroxiredoxin-2 (Prx2) inversely correlated with the metastatic capa... | [
{
"question": "What type of enzyme is peroxiredoxin 2 (PRDX2)?",
"answers": [
"antioxidant"
],
"qid": "4725ab4959074b2b82db8e9b8383de5d",
"question_tokens": [
[
"What",
0
],
[
"type",
5
],
[
"of",
10
],
... | [
[
"In",
0
],
[
"melanoma",
3
],
[
",",
11
],
[
"transition",
13
],
[
"to",
24
],
[
"the",
27
],
[
"vertical",
31
],
[
"growth",
40
],
[
"phase",
47
],
[
"is",
53
],
[
"the",
56
],
[
... | null |
Peroxiredoxin 2 (Prx2), a thiol-dependent peroxidase, is the third most abundant protein in the erythrocyte, and its absence in knock-out mice gives rise to hemolytic anemia. We have found that in human erythrocytes, Prx2 was extremely sensitive to oxidation by H(2)O(2), as dimerization was observed after exposure of 5... | [
{
"question": "What type of enzyme is peroxiredoxin 2 (PRDX2)?",
"answers": [
"antioxidant"
],
"qid": "e02be922827e4845bcfa8b7bbd3e8a3e",
"question_tokens": [
[
"What",
0
],
[
"type",
5
],
[
"of",
10
],
... | [
[
"Peroxiredoxin",
0
],
[
2,
14
],
[
"(",
16
],
[
"Prx2",
17
],
[
")",
21
],
[
",",
22
],
[
"a",
24
],
[
"thiol",
26
],
[
0,
31
],
[
"dependent",
32
],
[
"peroxidase",
42
],
[
",",... | null |
Peroxiredoxin-2 (PRDX-2) is an antioxidant and chaperone-like protein critical for cell function. This study examined whether the levels of lymphocyte PRDX-2 are altered over 1 month following ultra-endurance exercise. Nine middle-aged men undertook a single-stage, multi-day 233 km (145 mile) ultra-endurance running ra... | [
{
"question": "What type of enzyme is peroxiredoxin 2 (PRDX2)?",
"answers": [
"antioxidant"
],
"qid": "5972815d8210470eb84c3da30f0aa090",
"question_tokens": [
[
"What",
0
],
[
"type",
5
],
[
"of",
10
],
... | [
[
"Peroxiredoxin-2",
0
],
[
"(",
16
],
[
"PRDX-2",
17
],
[
")",
23
],
[
"is",
25
],
[
"an",
28
],
[
"antioxidant",
31
],
[
"and",
43
],
[
"chaperone",
47
],
[
0,
56
],
[
"like",
57
],
... | null |
Dendritic cells (DCs), professional antigen-presenting cells with the unique ability to initiate primary T-cell responses, are present in atherosclerotic lesions where they are exposed to oxidative stress that generates cytotoxic reactive oxygen species (ROS). A large body of evidence indicates that cell death is a maj... | [
{
"question": "What type of enzyme is peroxiredoxin 2 (PRDX2)?",
"answers": [
"antioxidant"
],
"qid": "e0afb40c95bf43ecb23eaab63790e3b4",
"question_tokens": [
[
"What",
0
],
[
"type",
5
],
[
"of",
10
],
... | [
[
"Dendritic",
0
],
[
"cells",
10
],
[
"(",
16
],
[
"DCs",
17
],
[
")",
20
],
[
",",
21
],
[
"professional",
23
],
[
"antigen",
36
],
[
0,
43
],
[
"presenting",
44
],
[
"cells",
55
],
... | null |
Using a rat model of L-DOPA-induced dyskinesia (LID), the contributions of dopamine D1 and D2 receptors to axial, limb, and orolingual (ALO) abnormal involuntary movements (AIMs) elicited by L-DOPA were examined. Chronic L-DOPA-treated rats received the D1 receptor antagonist SCH23390 (0.01, 0.1, and 1.0 mg/kg; i.p.), ... | [
{
"question": "Which drug is benserazide usually co-administered with?",
"answers": [
"L-Dopa"
],
"qid": "cef4a7fbb56948418ee4895ae79c5294",
"question_tokens": [
[
"Which",
0
],
[
"drug",
6
],
[
"is",
11
],... | [
[
"Using",
0
],
[
"a",
6
],
[
"rat",
8
],
[
"model",
12
],
[
"of",
18
],
[
"L",
21
],
[
0,
22
],
[
"DOPA",
23
],
[
0,
27
],
[
"induced",
28
],
[
"dyskinesia",
36
],
[
"(",
47
... | null |
Previously we reported on L-DOPA's antinociceptive effect on substance P-induced nociceptive behaviors in mice [Shimizu T, Iwata S, Morioka H, Masuyama T, Fukuda T, Nomoto M. Antinociceptive mechanism of L-DOPA. Pain 2004;110;246-9.]. Since significant hyperalgesia was noted following antinociception, our study was des... | [
{
"question": "Which drug is benserazide usually co-administered with?",
"answers": [
"L-Dopa"
],
"qid": "a599caa6467c4126af22518a18e24c41",
"question_tokens": [
[
"Which",
0
],
[
"drug",
6
],
[
"is",
11
],... | [
[
"Previously",
0
],
[
"we",
11
],
[
"reported",
14
],
[
"on",
23
],
[
"L",
26
],
[
0,
27
],
[
"DOPA",
28
],
[
"'s",
32
],
[
"antinociceptive",
35
],
[
"effect",
51
],
[
"on",
58
],
[
... | null |
L-DOPA-induced dyskinesia is a common side effect developed after chronic treatment with 3,4-dihydroxyphenyl-l-alanine (l-DOPA) in Parkinson's disease. The biological mechanisms behind this side effect are not fully comprehended although involvement of dopaminergic, serotonergic, and glutamatergic systems has been sugg... | [
{
"question": "Which drug is benserazide usually co-administered with?",
"answers": [
"L-Dopa"
],
"qid": "51cc9b8c720b4a8da80558914feaa7f7",
"question_tokens": [
[
"Which",
0
],
[
"drug",
6
],
[
"is",
11
],... | [
[
"L",
0
],
[
0,
1
],
[
"DOPA",
2
],
[
0,
6
],
[
"induced",
7
],
[
"dyskinesia",
15
],
[
"is",
26
],
[
"a",
29
],
[
"common",
31
],
[
"side",
38
],
[
"effect",
43
],
[
"developed",... | null |
Dopamine (DA) replacement therapy with l-DOPA remains the standard pharmacotherapy for Parkinson's disease (PD). Unfortunately, chronic l-DOPA treatment is accompanied by development of motor fluctuations and l-DOPA-induced dyskinesia (LID). While serotonin (5-HT)(1A) agonists acutely reduce these complications, their ... | [
{
"question": "Which drug is benserazide usually co-administered with?",
"answers": [
"L-Dopa"
],
"qid": "9109377696c0452b896a102d8836ded8",
"question_tokens": [
[
"Which",
0
],
[
"drug",
6
],
[
"is",
11
],... | [
[
"Dopamine",
0
],
[
"(",
9
],
[
"DA",
10
],
[
")",
12
],
[
"replacement",
14
],
[
"therapy",
26
],
[
"with",
34
],
[
"l",
39
],
[
0,
40
],
[
"DOPA",
41
],
[
"remains",
46
],
[
"th... | null |
Clozapine reduces L-3,4-dihydroxyphenylalanine (L-Dopa)-induced dyskinesias in parkinsonian patients. To test if the antidyskinetic effect of clozapine is related to antagonism at the dopamine D(4) receptor, we investigated the effect of 8-methyl-6-(4-methyl-1-piperazinyl)-11H-pyrido[2,3-b][1, 4]benzodiazepine (JL-18),... | [
{
"question": "Which drug is benserazide usually co-administered with?",
"answers": [
"L-Dopa"
],
"qid": "7084fb7065f745f3870b1046a517cc3a",
"question_tokens": [
[
"Which",
0
],
[
"drug",
6
],
[
"is",
11
],... | [
[
"Clozapine",
0
],
[
"reduces",
10
],
[
"L-3,4-dihydroxyphenylalanine",
18
],
[
"(",
47
],
[
"L",
48
],
[
0,
49
],
[
"Dopa)-induced",
50
],
[
"dyskinesias",
64
],
[
"in",
76
],
[
"parkinsonian",
79
... | null |
(S)-(-)-3-(3-(methylsulfonyl)phenyl)-1-propylpiperidine ((-)-OSU6162) is a phenylpiperidine derivative which exhibits low affinity to the dopamine D2 receptor in vitro. However, in vivo, positron emission tomography scanning studies show that the compound displaces the selective dopamine D2 receptor antagonist, raclopr... | [
{
"question": "Which drug is benserazide usually co-administered with?",
"answers": [
"L-Dopa"
],
"qid": "fd218c6955b9465b8d895d3154d58ebb",
"question_tokens": [
[
"Which",
0
],
[
"drug",
6
],
[
"is",
11
],... | [
[
"(",
0
],
[
"S)-(-)-3-(3-(methylsulfonyl)phenyl)-1-propylpiperidine",
1
],
[
"(",
56
],
[
"(",
57
],
[
"-)-OSU6162",
58
],
[
")",
68
],
[
"is",
70
],
[
"a",
73
],
[
"phenylpiperidine",
75
],
[
"derivati... | null |
The effect of levodopa (L-dopa), alone or in combination with a peripheral decarboxylase inhibitor (PDI), on plasma levels of aromatic-L-amino acid decarboxylase (ALAAD, = dopa decarboxylase), L-dopa, 3-O-methyl-dopa (3-OMD), dopamine (DA), noradrenaline, adrenaline and dopamine beta-hydroxylase has been studied. In he... | [
{
"question": "Which drug is benserazide usually co-administered with?",
"answers": [
"L-Dopa"
],
"qid": "5aad124ed6b3449e87579c5571aa6c64",
"question_tokens": [
[
"Which",
0
],
[
"drug",
6
],
[
"is",
11
],... | [
[
"The",
0
],
[
"effect",
4
],
[
"of",
11
],
[
"levodopa",
14
],
[
"(",
23
],
[
"L",
24
],
[
0,
25
],
[
"dopa",
26
],
[
")",
30
],
[
",",
31
],
[
"alone",
33
],
[
"or",
39
],... | null |
Dopa decarboxylase (DDC), a pyridoxal 5'-phosphate (PLP) enzyme responsible for the biosynthesis of dopamine and serotonin, is involved in Parkinson's disease (PD). PD is a neurodegenerative disease mainly due to a progressive loss of dopamine-producing cells in the midbrain. Co-administration of L-Dopa with peripheral... | [
{
"question": "Which drug is benserazide usually co-administered with?",
"answers": [
"L-Dopa"
],
"qid": "d11256fd28f844698bd688152f464ae5",
"question_tokens": [
[
"Which",
0
],
[
"drug",
6
],
[
"is",
11
],... | [
[
"Dopa",
0
],
[
"decarboxylase",
5
],
[
"(",
19
],
[
"DDC",
20
],
[
")",
23
],
[
",",
24
],
[
"a",
26
],
[
"pyridoxal",
28
],
[
"5'-phosphate",
38
],
[
"(",
51
],
[
"PLP",
52
],
[
... | null |
The mechanism of L-DOPA for antinociception was investigated. Nociceptive behaviors in mice after an intrathecal (i.t.) administration of substance P were evaluated. L-DOPA (i.t.) dose-dependently attenuated the substance P-induced nociceptive behaviors. Co-administration of benserazide (i.t.), a DOPA decarboxylase inh... | [
{
"question": "Which drug is benserazide usually co-administered with?",
"answers": [
"L-Dopa"
],
"qid": "b8c8036eed1c449eb5db1160c25e2ed4",
"question_tokens": [
[
"Which",
0
],
[
"drug",
6
],
[
"is",
11
],... | [
[
"The",
0
],
[
"mechanism",
4
],
[
"of",
14
],
[
"L",
17
],
[
0,
18
],
[
"DOPA",
19
],
[
"for",
24
],
[
"antinociception",
28
],
[
"was",
44
],
[
"investigated",
48
],
[
".",
60
],
[
... | null |
In vivo brain microdialysis was used to assess the effects of tolcapone, a novel central and peripheral inhibitor of catechol-O-methyltransferase on striatal 3,4-dihydroxyphenyl-L-alanine (L-dopa) and dopamine metabolism. The oral administration of 30 mg/kg of tolcapone failed to change dopamine output but elicited a m... | [
{
"question": "Which drug is benserazide usually co-administered with?",
"answers": [
"L-Dopa"
],
"qid": "08994280294d46b78596738f2a8bd39a",
"question_tokens": [
[
"Which",
0
],
[
"drug",
6
],
[
"is",
11
],... | [
[
"In",
0
],
[
"vivo",
3
],
[
"brain",
8
],
[
"microdialysis",
14
],
[
"was",
28
],
[
"used",
32
],
[
"to",
37
],
[
"assess",
40
],
[
"the",
47
],
[
"effects",
51
],
[
"of",
59
],
[
... | null |
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is caused by mutations in the NOTCH3 gene and is clinically characterized by recurrent stroke, cognitive decline, psychiatric disturbances and migraine. The prevalence of migraine in CADASIL is slightly higher than in t... | [
{
"question": "Which gene is involved in CADASIL?",
"answers": [
"Notch3 gene"
],
"qid": "56b8eb3015f747f78f3544b919c22c37",
"question_tokens": [
[
"Which",
0
],
[
"gene",
6
],
[
"is",
11
],
[
... | [
[
"Cerebral",
0
],
[
"autosomal",
9
],
[
"dominant",
19
],
[
"arteriopathy",
28
],
[
"with",
41
],
[
"subcortical",
46
],
[
"infarcts",
58
],
[
"and",
67
],
[
"leukoencephalopathy",
71
],
[
"(",
91
... | null |
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is a small vessel disease of the brain caused by mutations in the NOTCH3 gene. CADASIL progresses, in some cases, to subcortical dementia with a particular cognitive impairment. Different diseases in the dementia spectr... | [
{
"question": "Which gene is involved in CADASIL?",
"answers": [
"Notch3 gene"
],
"qid": "27c99f3d44a94401b785406bd2f20967",
"question_tokens": [
[
"Which",
0
],
[
"gene",
6
],
[
"is",
11
],
[
... | [
[
"Cerebral",
0
],
[
"autosomal",
9
],
[
"dominant",
19
],
[
"arteriopathy",
28
],
[
"with",
41
],
[
"subcortical",
46
],
[
"infarcts",
58
],
[
"and",
67
],
[
"leukoencephalopathy",
71
],
[
"(",
91
... | null |
To investigate the migraine locus around the C19p13 region through analysis of the NOTCH3 gene (C19p13.2-p13.1), previously shown to be a gene involved in CADASIL and the TNFSF7 gene (C19p13), homologous to the ligands of TNF-alpha and TNF-beta, genes that have previously been associated with migraine. The NOTCH3 gene ... | [
{
"question": "Which gene is involved in CADASIL?",
"answers": [
"Notch3 gene"
],
"qid": "fc24f2392a694a878abd703ed179be42",
"question_tokens": [
[
"Which",
0
],
[
"gene",
6
],
[
"is",
11
],
[
... | [
[
"To",
0
],
[
"investigate",
3
],
[
"the",
15
],
[
"migraine",
19
],
[
"locus",
28
],
[
"around",
34
],
[
"the",
41
],
[
"C19p13",
45
],
[
"region",
52
],
[
"through",
59
],
[
"analysis",
... | null |
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is a vascular dementing disease caused by mutations in the NOTCH3 gene, most which are missense mutations leading to an uneven number of cysteine residues in epidermal growth factor-like repeats in the extracellular dom... | [
{
"question": "Which gene is involved in CADASIL?",
"answers": [
"Notch3 gene"
],
"qid": "23e49b37f14a466999405fd5b5603a3b",
"question_tokens": [
[
"Which",
0
],
[
"gene",
6
],
[
"is",
11
],
[
... | [
[
"Cerebral",
0
],
[
"autosomal",
9
],
[
"dominant",
19
],
[
"arteriopathy",
28
],
[
"with",
41
],
[
"subcortical",
46
],
[
"infarcts",
58
],
[
"and",
67
],
[
"leukoencephalopathy",
71
],
[
"(",
91
... | null |
Cerebrolysin (Cere) is a peptidergic nootropic drug with neurotrophic properties which has been used to treat dementia and sequelae of stroke. Use of Cere prevents nuclear structural changes typical of apoptosis and significantly reduces the number of apoptotic cells after several apoptotic stimuli. Cerebral Autosomal ... | [
{
"question": "Which gene is involved in CADASIL?",
"answers": [
"Notch3 gene"
],
"qid": "af0fd3f5bf9540ba8eb2d1ef50fc1544",
"question_tokens": [
[
"Which",
0
],
[
"gene",
6
],
[
"is",
11
],
[
... | [
[
"Cerebrolysin",
0
],
[
"(",
13
],
[
"Cere",
14
],
[
")",
18
],
[
"is",
20
],
[
"a",
23
],
[
"peptidergic",
25
],
[
"nootropic",
37
],
[
"drug",
47
],
[
"with",
52
],
[
"neurotrophic",
57... | null |
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is an inherited small-artery disease of mid-adulthood caused by mutations of the NOTCH3 gene. The disease is responsible for widespread white-matter lesions associated with lacunar infarctions in various subcortical are... | [
{
"question": "Which gene is involved in CADASIL?",
"answers": [
"Notch3 gene"
],
"qid": "b2f73e6827624d46a50622245bc0bc8c",
"question_tokens": [
[
"Which",
0
],
[
"gene",
6
],
[
"is",
11
],
[
... | [
[
"Cerebral",
0
],
[
"autosomal",
9
],
[
"dominant",
19
],
[
"arteriopathy",
28
],
[
"with",
41
],
[
"subcortical",
46
],
[
"infarcts",
58
],
[
"and",
67
],
[
"leukoencephalopathy",
71
],
[
"(",
91
... | null |
Proteins of the Notch family are cell surface receptors that transduce signals between neighbouring cells. The Notch signalling pathway is highly evolutionarily conserved and critical for cell fate determination during embryonic development, including many aspects of vascular development. The interaction of Notch recep... | [
{
"question": "Which gene is involved in CADASIL?",
"answers": [
"Notch3 gene"
],
"qid": "2c9f414f7a3a499893e29b02c1e7994e",
"question_tokens": [
[
"Which",
0
],
[
"gene",
6
],
[
"is",
11
],
[
... | [
[
"Proteins",
0
],
[
"of",
9
],
[
"the",
12
],
[
"Notch",
16
],
[
"family",
22
],
[
"are",
29
],
[
"cell",
33
],
[
"surface",
38
],
[
"receptors",
46
],
[
"that",
56
],
[
"transduce",
61
... | null |
Notch3 is a single pass transmembrane protein belonging to the Notch receptor family. Notch proteins are involved in a very conserved signaling system (Notch signaling) with a broad spectrum of functions, from cell proliferation and differentiation to apoptosis. Mutations in Notch3 gene are linked to cerebral autosomal... | [
{
"question": "Which gene is involved in CADASIL?",
"answers": [
"Notch3 gene"
],
"qid": "966839ca942444edadde10ae73c038bf",
"question_tokens": [
[
"Which",
0
],
[
"gene",
6
],
[
"is",
11
],
[
... | [
[
"Notch3",
0
],
[
"is",
7
],
[
"a",
10
],
[
"single",
12
],
[
"pass",
19
],
[
"transmembrane",
24
],
[
"protein",
38
],
[
"belonging",
46
],
[
"to",
56
],
[
"the",
59
],
[
"Notch",
63
]... | null |
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), the most common form of familial vascular dementia, is caused by mutations of the NOTCH3 gene. Approximately two hundred pathogenic mutations have been reported within five exons (exons 3, 4, 6, 11 and 19) which accoun... | [
{
"question": "Which gene is involved in CADASIL?",
"answers": [
"Notch3 gene"
],
"qid": "33f0175a3dd1410a979d8698198ca39b",
"question_tokens": [
[
"Which",
0
],
[
"gene",
6
],
[
"is",
11
],
[
... | [
[
"Cerebral",
0
],
[
"autosomal",
9
],
[
"dominant",
19
],
[
"arteriopathy",
28
],
[
"with",
41
],
[
"subcortical",
46
],
[
"infarcts",
58
],
[
"and",
67
],
[
"leukoencephalopathy",
71
],
[
"(",
91
... | null |
To evaluate the role of apoptosis in the pathogenesis of brain lesions in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), a hereditary microangiopathy leading to cognitive decline and dementia, caused by mutations in the NOTCH3 gene. Detection of apoptotic nuclei in... | [
{
"question": "Which gene is involved in CADASIL?",
"answers": [
"Notch3 gene"
],
"qid": "63bd935131b94b97a6120e16b7ff3249",
"question_tokens": [
[
"Which",
0
],
[
"gene",
6
],
[
"is",
11
],
[
... | [
[
"To",
0
],
[
"evaluate",
3
],
[
"the",
12
],
[
"role",
16
],
[
"of",
21
],
[
"apoptosis",
24
],
[
"in",
34
],
[
"the",
37
],
[
"pathogenesis",
41
],
[
"of",
54
],
[
"brain",
57
],
[
... | null |
Gene expression signatures can provide an unbiased view into the molecular changes underlying biologically and medically interesting phenotypes. We therefore initiated this study to identify signatures that would be of utility in studying rheumatoid arthritis (RA). We used microarray profiling of peripheral blood monon... | [
{
"question": "Which is the most common gene signature in Rheumatoid Arthritis patients?",
"answers": [
"Interferon signature",
"IFN signature"
],
"qid": "445eaec1f42042ac82afda98668e9da8",
"question_tokens": [
[
"Which",
0
],
[
"is",
... | [
[
"Gene",
0
],
[
"expression",
5
],
[
"signatures",
16
],
[
"can",
27
],
[
"provide",
31
],
[
"an",
39
],
[
"unbiased",
42
],
[
"view",
51
],
[
"into",
56
],
[
"the",
61
],
[
"molecular",
... | null |
End of preview.
No dataset card yet
- Downloads last month
- 34